A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps



Status:Completed
Conditions:Sinusitis
Therapuetic Areas:Otolaryngology
Healthy:No
Age Range:18 - 75
Updated:4/6/2019
Start Date:November 15, 2017
End Date:March 11, 2019

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

The purpose of this study is to determine the efficacy and safety of omalizumab compared with
placebo in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who have
had an inadequate response to standard-of-care treatments.


Inclusion Criteria:

- Age 18-75 years, inclusive, at time of signing Informed Consent Form.

- Ability to comply with the study protocol, in the investigator's judgment.

- Nasal polyp score (NPS) >= 5, with a unilateral score of >= 2 for each nostril, at
screening (Day -35), and on Day -7.

- Sino-Nasal Outcome Test-22 (SNOT-22) score >=20 at screening (Day -35) and at
randomization (Day 1).

- Treatment with at least nasal mometasone 200 micro gram per day, or equivalent daily
dosing of nasal corticosteroid (CS), for at least 4 weeks before screening (Day -35).

- Treatment with nasal mometasone 200 micro gram twice a day (BID) (or once a day [QD]
if intolerant to twice daily) during the run-in period with an adherence rate of at
least 70%.

- Presence of nasal blockage/congestion with NCS >=2 (1-week recall) at Day -35 and an
average of the daily NCS score over the 7 days prior to randomization of NCS >1 with
at least one of the following symptoms prior to screening: nasal discharge
(anterior/posterior nasal drip) and/or reduction or loss of smell.

- Eligibility per the study drug dosing table

- Willingness to maintain all background medications stable for the duration of the
treatment and follow-up periods.

- Willingness and ability to use electronic device to enter study-related information in
electronic devices (electronic diary [eDiary]/electronic tablet [eTablet]).

- Demonstration of at least 70% adherence to eDiary daily symptom assessment during run
in period, with fully completed entries on at least 4 days in the week prior to
randomization.

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use acceptable contraceptive methods during the treatment
period and for 60 days after the last dose of study drug.

Exclusion Criteria:

- Known history of anaphylaxis/hypersensitivity to omalizumab.

- Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is
longer) prior to screening (Day -35).

- Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab) for 6 months
prior to screening (Day -35).

- Current treatment with leukotriene antagonists/modifiers, unless participant has been
on stable dosing of such medication for at least 1 month prior to screening (Day -35).

- Treatment with non-steroid immunosuppressants within 2 months or 5 half-lives,
whichever is longer, prior to screening (Day -35).

- Treatment with systemic corticosteroids, except when used as treatment for nasal
polyposis, within 2 months prior to screening (Day -35).

- Usage of systemic CS during the run-in period. Participants requiring systemic CS
during run-in may be rescreened after completing systemic CS.

- Treatment with intranasal CS drops or CS administering devices (e.g., OptiNose device
or stents) within 1 month prior to screening (Day -35) or during the run-in period.

- History of nasal surgery (including polypectomy) within 6 months prior to screening.

- History of sinus or nasal surgery modifying the structure of the nose such that
assessment of NPS is not possible.

- Uncontrolled epistaxis requiring surgical or procedural intervention, including nasal
packing, within 2 months prior to screening.

- Known or suspected diagnosis of cystic fibrosis, primary ciliary dyskinesia (e.g.,
Kartagener syndrome) or other dyskinetic ciliary syndromes, hypogammaglobulinemia or
other immune deficiency syndrome, chronic granulomatous disease and granulomatous
vasculitis, granulomatosis with polyangiitis (e.g., Wegener's Granulomatosis), or
eosinophilic granulomatous with polyangiitis (EGPA) (e.g., Churg-Strauss syndrome).

- Presence of antrochoanal polyps.

- Concomitant conditions that interfere with evaluation of primary endpoint:

- Nasal septal deviation occluding one or both nostrils.

- Ongoing rhinitis medicamentosa.

- Acute sinusitis, nasal infection, or upper respiratory infection during the
run-in period.

- Known or suspected invasive or expansive fungal rhinosinusitis.

- Known HIV infection at screening.

- Known acute and chronic infections with hepatitis C virus (HCV) and hepatitis B virus
(HBV) at screening.

- History of myocardial infarction, unstable angina, cerebrovascular accident, or
transient ischemic attack or a known history of a hypercoagulable disorder.

- Active tuberculosis requiring treatment within 12 months prior to screening (Day -35).

- Initiation of or change in allergen immunotherapy within 3 months prior to screening
(Day -35) or during the run-in period.

- Initiation of or change in aspirin desensitization within 4 months prior to screening
(Day -35) or during the run-in period.

- Pregnant or breastfeeding, or intending to become pregnant during the study or within
60 days after the last dose of omalizumab.

- Current malignancy or history of malignancy within 5 years prior to screening, except
for appropriately treated carcinoma in situ of the cervix or non-melanoma skin
carcinoma that has been treated or excised and is considered resolved.

- Any serious medical condition (including but not limited to significant arrhythmia,
uncontrolled hypertension, significant pulmonary disease other than asthma) or
abnormality in clinical laboratory tests that precludes the participant's safe
participation in and completion of the study.

- History of alcohol, drug, or chemical abuse within 6 months of screening.
We found this trial at
12
sites
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Charleston, South Carolina 29403
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Great Neck, New York 11021
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
Los Angeles, California 90025
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1101 Medical Center Boulevard
Marrero, Louisiana 70072
?
mi
from
Marrero, LA
Click here to add this to my saved trials
Miami, Florida 33135
?
mi
from
Miami, FL
Click here to add this to my saved trials
Missoula, Montana
?
mi
from
Missoula, MT
Click here to add this to my saved trials
?
mi
from
Ottawa,
Click here to add this to my saved trials
?
mi
from
Roseville, CA
Click here to add this to my saved trials
736 South 900 East
Saint George, Utah 84790
?
mi
from
Saint George, UT
Click here to add this to my saved trials
Twin Falls, Idaho 83301
?
mi
from
Twin Falls, ID
Click here to add this to my saved trials